KUALA LUMPUR: Private eye specialist Optimax Holdings Bhd posted a revenue of RM26.61 million for the fourth quarter (Q4) ended December 31, 2021 (FY21), an increase of 54.59 per cent from the RM17.21 million same quarter last year.
The increase in revenue is also supported by the net profit that rose 78.19 per cent to RM4.03 million compared to RM2.26 million for the same quarter last year.
The company's central Peninsular Malaysia operations remain the largest revenue contributor to revenue, at RM15.99 million or 60.08 per cent of total revenue for Q4 FY21.
North Peninsular Malaysia and South Peninsular Malaysia contributed RM5.16 million and RM4.95 million or 19.40 per cent and 18.59 per cent respectively to the total revenue, while East Malaysia contributed RM513,000 or 1.93 per cent of the total revenue.
For FY21, Optimax reported revenue of RM88.90 million, which is an increase of 53.22 per cent from the RM58.02 million reported in FY20.
Net profit was up 104.29 per cent or RM13.10 million compared to RM6.41 million for FY20.
Chief executive officer Sandy Tan said the company is gratified to see that the steady increase in revenue has once again supported profitability growth.
"We will continue to seek opportunities in 2022 that will strengthen our financial performance in the foreseeable future.
"The reopening of state borders, gradual recovery of economic activities and efficient roll-out of vaccination has been supportive of the rise in the number of patients, including those who postponed their refractive and cataract surgeries due to the movement restrictions.
"Patient numbers were also supported by the company's continued efforts to offer promotions online, which reflected positively on revenue," she said in a statement today.
Optimax is also involved in administering Covid-19 booster vaccination through participation in the National Covid-19 Immunisation Program (PICK) from the last financial quarter, further contributing positively to the company's revenue stream.
Optimax's recent corporate announcement includes signing a memorandum of understanding (MoU) with Selgate Healthcare Sdn Bhd at the end of 2021 to manage and operate a full-service eye specialist centre at Selgate's designated hospitals on an exclusive basis.
Optimax is also renovating an ambulatory care centre (ACC) in Bahau, Negeri Sembilan.
To date, Optimax is also setting up its first satellite clinic in Sutera, Johor Bahru.
"We are expanding our market reach in Malaysia and do not rule out expanding into South-East Asia in the future.
"We also believe that Optimax's prospects are favourable for the financial year ending December 31, 2022," Sandy said.
On February 24, 2022, the Optimax board declared a second interim tax-exempt dividend of 1.90 sen per ordinary share in respect of the financial year ended December 31, 2021.
The entitlement date is fixed on March 17, 2022, and the company will make payment on March 26, 2022.
The total dividends declared to date for the financial year ended December 31, 2021 is 3.80 sen per ordinary share.